Please assess the completion status of the following clinical trial:

Trial Title: CYP2B6 Polymorphisms in Methadone Disposition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each subject must meet all of the following criteria:~* 18-50 yr old~* CYP2B6\*1/\*1, CYP2B6\*1/\*6 or CYP2B6\*6/\*6 genotype~* Good general health with no remarkable medical conditions~* BMI \< 33~* Provided informed consent~Exclusion Criteria:~Subjects will not be enrolled if any of the following criteria exist:~* Known history of liver or kidney disease~* Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affect CYP2B6~* Females who are pregnant or nursing~* Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction)~* Direct physical access to and routine handling of addicting drugs in the regular course of duty (this is a routine exclusion from studies of drugs with addiction potential)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Methadone arm (Type: EXPERIMENTAL): 1. Intravenous racemic methadone HCl, 6.0 mg bolus~2. Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)

Based on this trial design, predict the completion outcome and termination type (if applicable).